Altis Labs raises $25M Series A for oncology AI — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Altis Labs raised a $25 million Series A, according to CEO Felix Baldauf-Lenschen, as reported by Axios
- Altis Labs' AI model analyzes CT scans taken during oncology drug trials and produces predictions tied to patient survival
Why it matters: The $25M Series A funds Altis Labs' AI platform that turns routine oncology CT scans into patient survival predictions — the same metric used as a primary efficacy endpoint in cancer drug trials, making the tool directly applicable to pharma sponsors evaluating trial outcomes.
Ask SkimNews
